Execs Cash Out While One CEO Doubles Down
The past two weeks of insider filings reveal a clear split: most US insiders were selling, but one biotech chief kept buying aggressively. The biggest buyer is SMMT Summit Therapeutics CEO Bob Duggan, who filed a $50M…